View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 30, 2019

Celgene partners Triphase for preclinical blood cancer candidate

Biopharmaceutical company Celgene has partnered with Canada-based drug development firm Triphase Accelerator for a preclinical drug candidate, TRPH-395, designed to treat blood cancers.

Biopharmaceutical company Celgene has partnered with Canada-based drug development firm Triphase Accelerator for a preclinical drug candidate, TRPH-395, designed to treat blood cancers.

Focused on oncology, Triphase Accelerator was founded by the Ontario Institute for Cancer Research (OICR), in alliance with MaRS Innovation and MaRS.

The deal also involves Triphase’s majority shareholder FACIT, and is intended to help the company to advance its therapeutic programme into clinical proof-of-concept studies.

FACIT seed financed Propellon Therapeutics to commercialise the preclinical candidate, which targets the WDR5 protein that is associated with the formation and activity of some protein complexes related to DNA and indirectly modify genes.

Inadequate regulation of WDR5-associated protein complexes could lead to development of blood cancers such as leukaemia.

Compounds targeting these cancer-causing cellular activities are expected to offer a new approach for treatment and improving patient outcomes.

Under the terms of the deal, Celgene holds an option to buy TRPH-395 from Triphase Accelerator.

“The teams at OICR Drug Discovery, FACIT and Triphase Accelerator have together created an optimal pathway for oncology innovation and help make Ontario a strong collaborator and destination for our investment.”

Celgene will make an upfront payment of $40m. Upon exercising the option, the company will additionally pay up to $940m in contingent development, regulatory and sales milestones.

Celgene Translational Development vice-president Jorge DiMartino said: “Our investment in Propellon’s technology reflects our commitment to developing first-in-class epigenetic therapies for patients with haematological cancers.

“The teams at OICR Drug Discovery, FACIT and Triphase Accelerator have together created an optimal pathway for oncology innovation and help make Ontario a strong collaborator and destination for our investment.”

Celgene and Triphase Accelerator have a long-standing oncology drug development partnership. In 2016, Celgene purchased assets to the latter’s proteasome inhibitor drug, called marizomib.

Earlier this month, Celgene signed a definitive merger agreement to be acquired by Bristol-Myers Squibb for a total consideration of $74bn.

The combination is set to create a speciality biopharma company focused on cancer, inflammation and immunologic diseases and cardiovascular disorders.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology